A Phase IIIB, Multinational, Multicenter, Randomized, Open-Label Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants with Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer
Latest Information Update: 27 May 2025
At a glance
- Drugs Pertuzumab (Primary) ; Pertuzumab/trastuzumab (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer; Inflammatory breast cancer; Male breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms ProHer
- Sponsors Roche
Most Recent Events
- 18 Mar 2024 Planned primary completion date changed from 5 Aug 2024 to 31 Mar 2025.
- 18 Mar 2024 Planned End Date changed from 25 Sep 2025 to 31 Dec 2025.
- 25 Oct 2023 Status changed from recruiting to active, no longer recruiting.